Chongqing Sintaho Pharmaceutical Co., Ltd. (hereinafter called “Sintaho”), founded in 2016, is a leading Active Pharmaceutical Ingredient (API) enterprise with distinctive characteristics, perfect GMP supporting systems, and long-time GMP compliance. Sintaho has full chain operation capabilities spanning R&D, production, registration, domestic and international marketing of APIs. Over the years, Sintaho has been honored with numerous titles, including National High-tech Enterprise, National Specialized and Sophisticated “Little Giant” firm, Chongqing Enterprise Technology Center, and Chongqing Hazardous Waste Management Benchmark Enterprise，In 2024, successfully passed the on-site inspection of the US FDA.

Sintaho's predecessor was"Chongqing Taihao Pharmaceutical Co.,Ltd. "Over the course of many years of development, it has cultivated a core management team with rich experience in R&D, Quality, Production, and Regulatory. The team has extensive experience in passing audits and inspections by domestic and international drug regulatory authorities such as NMPA, FDA, EDQM, and PMDA.

Sintaho focuses on three primary business segments: High-potency/Cytotoxic APIs, Peptides, and XDC Compounds. The product applications have been approved by more than 30 countries such as China, the United States, Canada and the European Union, resulting in product sales thereof. Sintaho is able to provide sophisticated CDMO and CMO services to our global partners by owning the dedicated cytotoxic API production lines, OEB5-level high-potency API production lines, and peptide production lines.

Sintaho is driven by its mission to “produce high-quality medicines to serve human health” and upholds core values of “people-oriented integrity, professional rigor, and innovative development.” It is dedicated to becoming a trusted API supplier in the global pharmaceutical supply chain.